SCHEMBL1197948

SCHEMBL1197948

[c]1nnnn1C(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
KCNN4 O15554 3/20 0.31
TSHR P16473 3/20 0.31
KCNA3 P22001 2/20 0.31
ALDH1A1 P00352 1/20 0.31
MEN1 O00255 1/20 0.30
SLC22A1 O15245 1/20 0.30
NR1I2 O75469 1/20 0.30
GMNN O75496 1/20 0.30
USP2 O75604 1/20 0.30
TRPM2 O94759 1/20 0.30
ABCB11 O95342 1/20 0.30
EGFR P00533 1/20 0.30
CA2 P00918 1/20 0.30
LMNA P02545 1/20 0.30
NR3C1 P04150 1/20 0.30
ERBB2 P04626 1/20 0.30
TP53 P04637 1/20 0.30
CYP17A1 P05093 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1756774 0.69 CYP11B1 (0.36) CYP11B1CYP11B2KCNN4TSHRKCNA3
SCHEMBL8443085 0.65 CYP11B1 (0.36) CYP11B1CYP11B2KCNN4TSHRKCNA3
SCHEMBL2036810 0.65 CYP11B1 (0.36) CYP11B1CYP11B2KCNN4TSHRKCNA3
SCHEMBL1757361 0.65 CYP11B1 (0.40) CYP11B1CYP11B2KCNN4TSHRKCNA3
SCHEMBL9650536 0.62 CYP2B6 (0.46) CYP11B1CYP11B2KCNN4TSHRALDH1A1
SCHEMBL198143 0.62 NOTUM (0.45) CYP11B1CYP11B2KCNN4TSHRKCNA3
SCHEMBL29268367 0.61 HTT (0.38) CYP11B1CYP11B2KCNN4TSHRKCNA3
SCHEMBL1292257 0.61 CYP11B1 (0.44) CYP11B1CYP11B2KCNN4TSHRKCNA3
SCHEMBL12787567 0.60 ALDH1A1 (0.39) CYP11B1CYP11B2TSHRALDH1A1LMNA
SCHEMBL30577371 0.59 CYP11B1 (0.57) CYP11B1CYP11B2KCNN4TSHRKCNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2513046-B1 PROCESS FOR THE PREPARATION OF 4-BROMOMETHYL-[1,1'-BIPHENYL]-2'-CARBONITRILE SANOFI SA (FR) 2015-07-08 EP claimed
EP-1032557-B1 METHOD FOR PREPARING BROMOMETHYL-BIPHENYL DERIVATIVES SANOFI SYNTHELABO (FR) 2003-09-10 EP claimed
US-20020183313-A1 1,4-benzodiazepinones and their uses as CCK antagonists FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-12-05 US claimed
US-20020002163-A1 1,4-benzodiazepinones and their uses as CCK antagonists FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-01-03 US claimed
US-6291452-B1 CHOLECYSTOKININ ANTAGONISTS. FUJISAWA PHARMACETICAL CO., LTD. (JP) 2001-09-18 US claimed
US-6214999-B1 A BROMINATING AGENT IS REACTED IN A 2 PHASE MEDIUM, UNDER EFFECT PHOTO-IRRADIATION WITH BIPHENYL DERIVATIVE SANOFI-SYNTHELABO (FR) 2001-04-10 US claimed
EP-1032557-A1 METHOD FOR PREPARING BROMOMETHYL-BIPHENYL DERIVATIVES SANOFI-SYNTHELABO (FR) 2000-09-06 EP claimed
EP-0934282-A1 1,4-BENZODIAZEPINONES AND THEIR USES AS CCK ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-08-11 EP claimed
WO-1999025681-A1 METHOD FOR PREPARING BROMOMETHYL-BIPHENYL DERIVATIVES SANOFI-SYNTHELABO (FR) 1999-05-27 WO claimed
WO-1998015535-A1 1,4-BENZODIAZEPINONES AND THEIR USES AS CCK ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-04-16 WO claimed
EP-0566020-A1 Benzimidazoles, pharmaceutical compositions thereof and processes for their preparation Dr. Karl Thomae GmbH (DE) 1993-10-20 EP claimed
EP-0560330-A2 Substituted benzimidazolyl derivatives, therapeutic agents containing them and process for their preparation Dr. Karl Thomae GmbH (DE) 1993-09-15 EP claimed
EP-0556789-A2 Substituted biphenyl derivatives, therapeutic agents containing them and process for their preparation Dr. Karl Thomae GmbH (DE) 1993-08-25 EP claimed
EP-0555825-A1 Imidazo(1,2-a)pyridines as angiotensin-II-antagonists Dr. Karl Thomae GmbH (DE) 1993-08-18 EP claimed
EP-0552765-A1 Benzimidazoles, pharmaceutical compositions containing them and process for their preparation Dr. Karl Thomae GmbH (DE) 1993-07-28 EP claimed
EP-0479892-A1 FUSED-RING ARYL SUBSTITUTED IMIDAZOLES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1992-04-15 EP claimed
WO-1991000277-A1 SUBSTITUTED IMIDAZOLES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-01-10 WO claimed
WO-1991000281-A2 FUSED-RING ARYL SUBSTITUTED IMIDAZOLES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-01-10 WO claimed
EP-0324377-A2 Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-07-19 EP claimed
WO-1989006233-A1 ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES AND COMBINATIONS THEREOF WITH DIURETICS AND NSAIDS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-07-13 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020002163-A1 1,4-benzodiazepinones and their uses as CCK antagonists CCKAR, CCKBR, GABRA4 CYP11B1 212/4885CYP11B2 259/4885KCNN4 262/4885
US-20020183313-A1 1,4-benzodiazepinones and their uses as CCK antagonists CCKAR, CCKBR, GABRA4 CYP11B1 212/4885CYP11B2 259/4885KCNN4 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.